65,437 trials
Type 2 Diabetes Mellitus
Primary: Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months. — 53.9; 60.6; 67.8; 70.6 probability (%)
Breast Cancer
Primary: Sensitivity on the Per Patient Level — 25; 27 participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Non-Progression at Week 8 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 76.9; 80.3 percentage of participants
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR) — 27; 29 Number of participants with SVR
Femur Fracture
Primary: Difference in the Two Groups in Regards to Resident Time. — 24; 57 minutes
Pulmonary Disease, Chronic Obstructive
Primary: Adjusted Mean Endurance Time After 6 Weeks — 354.33; 396.31; 391.45 seconds — p=0.0018
Allergic Rhinitis
Primary: Change in Tryptase Level From Baseline to Post-antigen Challenge — 0; 2.31 mcg/L — p=0.33
Cytomegalovirus Infections
Primary: Cellular Immune Response in Vaccine Recipients — 14 participants
Osteoarthritis
Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) — 43.3; 34.1 units on a scale
Retinopathy of Prematurity · Neonatal Cholestasis
Primary: Number of Participants With Retinopathy of Prematurity — 2; 13 participants
Parkinson's Disease
Primary: Incidence of Adverse Events — 105; 56 participants
Device Ineffective
Primary: Proportion of Volunteers'Perception of Needle Penetration Between the Pragmatic Placebo Needle and Real Needle. — 1; 0; 29; 30 participants — p=>0.05
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Coronary Artery Diseases
Primary: 30-day Composite Major Adverse Cardiac Event (MACE) — 256; 83 participants
Inflammation
Primary: Reduced Glutathione (GSH) Concentrations in Red Blood Cells — 1.38; 1.22; 1.23; 1.12 mmol/L